A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)

This study is testing whether adding an immunotherapy drug (toripalimab, a PD-1 antibody that helps the immune system fight cancer) to standard chemotherapy and radiation improves outcomes for patients with newly diagnosed early-stage natural killer/T-cell lymphoma (ENKTL), a rare type of lymphoma that most commonly affects the nose and upper throat. **You may be eligible if:** - You have a confirmed diagnosis of early-stage (stage I or II) extranodal NK/T-cell lymphoma, nasal type - You have not received any prior treatment for this lymphoma - You have at least one measurable area of disease on scans - You are in reasonably good health (ECOG performance status 0–2) - You are 18 to 75 years old - Your major organs (heart, kidneys, liver) are functioning adequately **You may NOT be eligible if:** - You have a severe complication of lymphoma called hemophagocytic syndrome or aggressive NK cell leukemia - Your lymphoma has spread to the central nervous system (brain or spinal cord) - You have previously received chemotherapy, radiation, immunotherapy, or other cancer treatments for this condition Talk to your doctor to see if this trial is right for you.